NEW YORK, NY -- (MARKET WIRE) -- May 15, 2007 -- Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced first quarter earnings for 2007. For the three months ended March 31, 2007 total operating revenues increased by 48% to $505,882 from $342,146 in 2006. This increase is directly attributed to the sale of two instruments in Q1 2007 vs. none in Q1 2006. Also, Volumex kit sales for 2007 were up by 21% over the prior year. Total cost and expenses increased by only 6% to $ 1,711,749 from $ 1,614,265 in 2006. At March 31, 2007 the Company had total assets of $83,468,271 with stockholders' equity of $ 51,343,092 vs. total assets of $78,166,312 and $45,637,792 of stockholders' equity for December 31, 2006.
